Empery Asset Management, LP
recently revealed that they own 5.5% of OpGen, Inc. (NASDAQ:OPGN) in a Schedule 13G disclosure that was filed with the Securities and Exchange Commission (SEC) on Tuesday, July 18th. The investor owns 2,500,000 shares of the stock worth about $755,000. The reporting parties listed on the disclosure included Empery Asset Management, LP, Ryan M Lane and Martin D Hoe. The disclosure is available through Edgar at this link.
Empery Asset Management, LP
provided the following explanation of their ownership:
Warning: file_get_contents(): php_network_getaddresses: getaddrinfo failed: Name or service not known in /home/acctmp/public_html/download.php on line 6
Warning: file_get_contents(https://whalewisdom.com
2,500,000
): failed to open stream: php_network_getaddresses: getaddrinfo failed: Name or service not known in /home/acctmp/public_html/download.php on line 6
Shares of OpGen, Inc. (NASDAQ:OPGN) traded down 1.016% during trading on Tuesday, reaching $0.302. 2,630,181 shares of the company traded hands. The company’s market capitalization is $8.27 million. The stock’s 50 day moving average is $0.70 and its 200 day moving average is $1.00. OpGen, Inc. has a 1-year low of $0.29 and a 1-year high of $4.65.
COPYRIGHT VIOLATION NOTICE: This piece of content was posted by StockNewsTimes and is the sole property of of StockNewsTimes. If you are viewing this piece of content on another website, it was copied illegally and reposted in violation of U.S. and international trademark & copyright law. The correct version of this piece of content can be accessed at https://stocknewstimes.com/2017/07/18/empery-asset-management-lp-owns-5-5-stake-in-opgen-inc-nasdaqopgn.html.
Several brokerages recently commented on OPGN. HC Wainwright set a $1.00 price objective on shares of OpGen and gave the company a “buy” rating in a research report on Tuesday. Dawson James reiterated a “buy” rating on shares of OpGen in a report on Monday, June 19th. Finally, Zacks Investment Research upgraded shares of OpGen from a “sell” rating to a “hold” rating in a report on Wednesday, June 28th.
OpGen Company Profile
OpGen, Inc (OpGen) is a precision medicine company using molecular diagnostics and informatics to combat infectious disease. The Company is engaged in developing molecular information solutions to combat infectious disease in global healthcare settings, helping to guide clinicians with information about life threatening infections, managing patient outcomes, and the spread of infections caused by multidrug-resistant microorganisms.
Want to see what other hedge funds are holding OPGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for OpGen, Inc. (NASDAQ:OPGN).
Receive News & Ratings for OpGen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OpGen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
